Literature DB >> 19727561

Microvascular leakage and contrast enhancement as prognostic factors for recurrence in unfavorable low-grade gliomas.

F Dhermain1, G Saliou, F Parker, P Page, K Hoang-Xuan, C Lacroix, E Tournay, J Bourhis, D Ducreux.   

Abstract

Perfusion estimates and microvascular leakage (MVL) were recently correlated with glioma angiogenesis and aggressiveness, but their role in predicting outcome of patients (pts) with unfavorable low-grade gliomas (ULGG) is unclear. Their prognostic value was then investigated, versus conventional factors such as age, neurological status, tumor size, and contrast enhancement (CE). Clinical and anatomical magnetic resonance imaging (MRI) criteria of a cohort of ULGG pts were prospectively evaluated. A dynamic T2*-weighted MR sequence was included to detect high-perfusion areas, using the maximal value of the relative cerebral blood volume (rCBV) estimate, and MVL. Conventional and microvascular characteristics were correlated with progression-free survival (PFS). Among the 46 pts included, the following features were present in 61%, 26%, 67%, and 26%, respectively: age >or=40 years, neurological deficits, tumor size >or=6 cm, and CE. High perfusion value was noted in 30% of cases and MVL in 52%. With median follow-up of 22 months (range 4-46 months), median PFS was 32 months [95% confidence interval (CI) 17-45 months]. On univariate analysis, CE, rCBV, and MVL were significantly correlated with PFS. On multivariate analysis, only CE and MVL were unfavorable factors, with hazard ratio of 3.0 and 7.3 and P value of 0.04 and 0.02, respectively. Different prognostic subgroups were identified, with 2-year PFS of 86%, 57%, and 19% for pts with no MVL, MVL without CE, and MVL with CE, respectively. MVL and CE seem to predict short-term outcome in ULGG pts.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19727561     DOI: 10.1007/s11060-009-9992-3

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  25 in total

1.  Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging--prediction of patient clinical response.

Authors:  Meng Law; Sarah Oh; James S Babb; Edwin Wang; Matilde Inglese; David Zagzag; Edmond A Knopp; Glyn Johnson
Journal:  Radiology       Date:  2006-01-05       Impact factor: 11.105

2.  Permeability versus cerebral blood volume measurement in brain tumor evaluation: comparative clinical value and advice to authors.

Authors:  Michael H Lev; Leonardo Vedolin
Journal:  AJNR Am J Neuroradiol       Date:  2006-02       Impact factor: 3.825

3.  Perfusion imaging with NMR contrast agents.

Authors:  B R Rosen; J W Belliveau; J M Vevea; T J Brady
Journal:  Magn Reson Med       Date:  1990-05       Impact factor: 4.668

4.  Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: a retrospective study in 379 patients.

Authors:  K Lote; T Egeland; B Hager; B Stenwig; K Skullerud; J Berg-Johnsen; I Storm-Mathisen; H Hirschberg
Journal:  J Clin Oncol       Date:  1997-09       Impact factor: 44.544

5.  Comparing perfusion metrics obtained from a single compartment versus pharmacokinetic modeling methods using dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade.

Authors:  M Law; R Young; J Babb; M Rad; T Sasaki; D Zagzag; G Johnson
Journal:  AJNR Am J Neuroradiol       Date:  2006-10       Impact factor: 3.825

6.  Prognostic factors for survival in adult patients with cerebral low-grade glioma.

Authors:  Francesco Pignatti; Martin van den Bent; Desmond Curran; Channa Debruyne; Richard Sylvester; Patrick Therasse; Denes Afra; Philippe Cornu; Michel Bolla; Charles Vecht; Abul B M F Karim
Journal:  J Clin Oncol       Date:  2002-04-15       Impact factor: 44.544

7.  Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.

Authors:  G Kaloshi; A Benouaich-Amiel; F Diakite; S Taillibert; J Lejeune; F Laigle-Donadey; M-A Renard; W Iraqi; A Idbaih; S Paris; L Capelle; H Duffau; P Cornu; J-M Simon; K Mokhtari; M Polivka; A Omuro; A Carpentier; M Sanson; J-Y Delattre; K Hoang-Xuan
Journal:  Neurology       Date:  2007-05-22       Impact factor: 9.910

8.  High cerebral blood volume in human gliomas predicts deletion of chromosome 1p: Preliminary results of molecular studies in gliomas with elevated perfusion.

Authors:  Meng Law; Jennie E Brodsky; James Babb; Marc Rosenblum; Douglas C Miller; David Zagzag; Michael L Gruber; Glyn Johnson
Journal:  J Magn Reson Imaging       Date:  2007-06       Impact factor: 4.813

9.  Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade.

Authors:  H C Roberts; T P Roberts; R C Brasch; W P Dillon
Journal:  AJNR Am J Neuroradiol       Date:  2000-05       Impact factor: 4.966

10.  The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations.

Authors:  M O Leach; K M Brindle; J L Evelhoch; J R Griffiths; M R Horsman; A Jackson; G C Jayson; I R Judson; M V Knopp; R J Maxwell; D McIntyre; A R Padhani; P Price; R Rathbone; G J Rustin; P S Tofts; G M Tozer; W Vennart; J C Waterton; S R Williams; P Workman
Journal:  Br J Cancer       Date:  2005-05-09       Impact factor: 7.640

View more
  8 in total

1.  Progranulin overexpression predicts overall survival in patients with glioblastoma.

Authors:  Minqing Wang; Gang Li; Junyi Yin; Tao Lin; Jian Zhang
Journal:  Med Oncol       Date:  2011-12-13       Impact factor: 3.064

2.  PWI-MRI and contrast extravasation in brain AVM help to estimate angiogenic activity.

Authors:  Guillaume Saliou; Timo Krings; Dik R Rutgers; Frederique Toulgoat; Augustin Ozanne; Pierre Lasjaunias; Denis Ducreux
Journal:  Neuroradiology       Date:  2011-05-12       Impact factor: 2.804

3.  A case report of pseudoprogression followed by complete remission after proton-beam irradiation for a low-grade glioma in a teenager: the value of dynamic contrast-enhanced MRI.

Authors:  Candice Meyzer; Frédéric Dhermain; Denis Ducreux; Jean-Louis Habrand; Pascale Varlet; Christian Sainte-Rose; Christelle Dufour; Jacques Grill
Journal:  Radiat Oncol       Date:  2010-02-04       Impact factor: 3.481

Review 4.  Radiotherapy of high-grade gliomas: current standards and new concepts, innovations in imaging and radiotherapy, and new therapeutic approaches.

Authors:  Frederic Dhermain
Journal:  Chin J Cancer       Date:  2014-01

5.  Prediction of IDH Status Through MRI Features and Enlightened Reflection on the Delineation of Target Volume in Low-Grade Gliomas.

Authors:  Haixia Ding; Yong Huang; Zhiqiang Li; Sirui Li; Qiongrong Chen; Conghua Xie; Yahua Zhong
Journal:  Technol Cancer Res Treat       Date:  2019-01-01

6.  The combination of novel targeted molecular agents and radiation in the treatment of pediatric gliomas.

Authors:  Tina Dasgupta; Daphne A Haas-Kogan
Journal:  Front Oncol       Date:  2013-05-10       Impact factor: 6.244

Review 7.  Incorporating prognostic imaging biomarkers into clinical practice.

Authors:  W Phillip Law; Kenneth A Miles
Journal:  Cancer Imaging       Date:  2013-09-23       Impact factor: 3.909

Review 8.  The role of imaging in the management of adults with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.

Authors:  Sarah Jost Fouke; Tammie Benzinger; Daniel Gibson; Timothy C Ryken; Steven N Kalkanis; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2015-11-03       Impact factor: 4.130

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.